A Phase 3 interventional study of KarXT in Schizophrenia, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.
Among the 20 studies testing xanomeline in Schizophrenia, this one is the 11th largest by enrollment, is the only one that started in 2024, is one of 14 in phase 3, and was the 10th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Argentina, Bulgaria and 4 more countries
Ages 18–65
New York State Psychiatric Institute · Sites in United States
Ages 18–50
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Australia, Canada and 8 more countries
Ages 5–17
Bristol-Myers Squibb · Sites in United States, Colombia, Japan and 1 more country
Ages 13–17
Bristol-Myers Squibb · Sites in United States
Ages 18–65
By country, each count listing its studies:
xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 14 · Phase 4 3
First in 2018; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 173 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 20 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 7 most frequent:
This study is registered under Karuna Therapeutics, Inc., a Bristol Myers Squibb company, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
21 studies in Schizophrenia by Bristol-Myers Squibb: 8 open now, 9 under way, 4 of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 21 studies in Schizophrenia by Bristol-Myers Squibb, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2024, is one of 13 in phase 3, and was the 11th registered.
Bristol-Myers Squibb’s Schizophrenia studies by the year they started, since 2016.
2 of the studies testing xanomeline in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07423546New York State Psychiatric InstituteA PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia | 2027-04-30 |
| NCT07061288Bristol-Myers SquibbA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing xanomeline in Schizophrenia, from their registry updates:
Among Bristol-Myers Squibb’s 21 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KarXT
Drug pages: Xanomeline · Trospium
Specified dose on specified days
Also known as: BMS-986510
Number of Participants With TEAEs From First Dose to End of Study Follow up.
Number of participants with Treatment Emergent Adverse Events (TEAEs) from first dose to end of study follow up. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
Time frame: From first dose to end of study follow up (63 days)
Number of Participants With TEAEs at the End of Period 1 and Period 2.
Number of participants with TEAEs at the end of period 1 and period 2. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
Time frame: Period 1 (From first dose to day 28) Period 2 (day 29 to day 56)
Number of Participants With Serious TEAEs at the End of Period 1 and Period 2.
Number of participants with TEAEs at the end of period 1 and period 2. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
Number of Participants With TEAEs Leading to Treatment Discontinuation.
Number of participants with TEAEs leading to treatment discontinuation.
Time frame: Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
Number of Participants With Pro-cholinergic and Anticholinergic TEAEs.
The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.
Time frame: Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
Change From Baseline in PANSS Total Score, Positive Score and Negative Score
The Positive and Negative Syndrome Scale (PANSS) assesses schizophrenia symptom severity using 30 items: 7 positive, 7 negative, and 16 general psychopathology scales. Each item is rated from 1 (absent) to 7 (extreme). Positive symptoms represent excesses or distortions of normal function (e.g., hallucinations, delusions), while negative symptoms reflect diminished function. The PANSS positive and negative scores each sum their respective 7 items, ranging from 7 to 49, with higher scores indicating greater severity. The PANSS Total Score sums all 30 items, ranging from 30 to 210, with higher scores reflecting worse overall symptom severity.
Time frame: From first dose to end of treatment (56 days)
Change From Baseline in Marder Factor Score.
PANSS Marder factor score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale, with a total score ranging from 7 to 49. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Baseline is defined as the PANSS score at screening.
Time frame: From first dose to end of treatment (56 days)
Change From Baseline in CGI Severity Score
Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness.
Time frame: From first dose to end of treatment (56 days)
Number of Participants With Spontaneously Reported AESIs
The AEs of special interest (AESIs) will be monitored and include symptomatic orthostasis, syncope(a transient loss of consciousness or fainting),and liver function test elevations as defined below. For SAE reporting requirements for events of liver injury.
Time frame: From first dose to end of study follow up (63 days)
Number of Participants With Clinically Significant Changes in Vital Signs
Number of participants with clinically significant changes in vital signs
Time frame: From first dose to end of study follow up (63 days)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
Number of participants with clinically significant changes in clinical laboratory assessments
Time frame: From first dose to end of study follow up (63 days)
Number of Participants With Clinically Significant Changes in 12-lead ECGs
Number of participants with clinically significant changes in 12-lead ECGs
Time frame: From first dose to end of study follow up (63 days)
Number of Participants Who Exhibited Suicidal Behavior as Assessed by C-SSRS
Number of participants who exhibited suicidal behavior as assessed by C-SSRS
Time frame: From first dose to end of study follow up (63 days)
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 100 | 73 |
| Completed | 83 | 56 |
| Not completed | 17 | 17 |
| Withdrew: Requested to discontinue study treatment | 14 | 11 |
| Withdrew: Adverse event | 1 | 6 |
| Withdrew: Other reasons | 1 | 0 |
| Withdrew: No longer meets study critieria | 1 | 0 |
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 100 | 73 |
| Completed | 83 | 53 |
| Not completed | 17 | 20 |
| Withdrew: Withdrawal of consent by participant | 13 | 16 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Other reasons | 1 | 1 |
| Withdrew: No longer meets study criteria | 1 | 0 |
The Positive and Negative Syndrome Scale (PANSS) assesses schizophrenia symptom severity using 30 items: 7 positive, 7 negative, and 16 general psychopathology scales. Each item is rated from 1 (absent) to 7 (extreme). Positive symptoms represent excesses or distortions of normal function (e.g., hallucinations, delusions), while negative symptoms reflect diminished function. The PANSS positive and negative scores each sum their respective 7 items, ranging from 7 to 49, with higher scores indicating greater severity. The PANSS Total Score sums all 30 items, ranging from 30 to 210, with higher scores reflecting worse overall symptom severity.
| Score on a Scale | Cohort 1 | Cohort 2 |
|---|---|---|
| Total Score | -3.9 ± 8.98 | -2.7 ± 7.40 |
| Positive Score | -1.7 ± 3.37 | -0.9 ± 2.40 |
| Negative Score | -0.7 ± 3.15 | -0.9 ± 2.34 |
PANSS Marder factor score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale, with a total score ranging from 7 to 49. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Baseline is defined as the PANSS score at screening.
| Score on a Scale | Cohort 1 | Cohort 2 |
|---|---|---|
| Change From Baseline in Marder Factor Score. | -1.2 ± 3.07 | 14.5 ± 3.76 |
Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness.
| Score on a Scale | Cohort 1 | Cohort 2 |
|---|---|---|
| Change From Baseline in CGI Severity Score | -0.2 ± 0.66 | -0.1 ± 0.50 |
The AEs of special interest (AESIs) will be monitored and include symptomatic orthostasis, syncope(a transient loss of consciousness or fainting),and liver function test elevations as defined below. For SAE reporting requirements for events of liver injury.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Number of Participants With Spontaneously Reported AESIs | 2 | 1 |
Number of participants with clinically significant changes in vital signs
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 |
Number of participants with clinically significant changes in clinical laboratory assessments
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | 0 | 0 |
Number of participants with clinically significant changes in 12-lead ECGs
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Number of Participants With Clinically Significant Changes in 12-lead ECGs | 0 | 0 |
Number of participants who exhibited suicidal behavior as assessed by C-SSRS
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Number of Participants Who Exhibited Suicidal Behavior as Assessed by C-SSRS | 0 | 0 |
Number of participants with Treatment Emergent Adverse Events (TEAEs) from first dose to end of study follow up. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| TEAE | 72 | 55 |
| Treatment Related TEAEs | 61 | 44 |
Number of participants with TEAEs at the end of period 1 and period 2. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Period 1 (First dose to day 28) | 62 | 49 |
| Period 2 (from day 29 to day 56) | 34 | 26 |
Number of participants with TEAEs at the end of period 1 and period 2. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Period 1 (First dose to day 28) | 0 | 0 |
| Period 2 (from day 29 to day 56) | 0 | 0 |
| From First dose to day 63 | 0 | 0 |
Number of participants with TEAEs leading to treatment discontinuation.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Period 1 (First dose to day 28) | 1 | 2 |
| Period 2 (from day 29 to day 56) | 0 | 3 |
| From First dose to day 63 | 1 | 5 |
The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Period 1 Procholinergic | 31 | 21 |
| Period 1 Anticholinergic | 34 | 27 |
| Period 2 Procholinergic | 13 | 6 |
| Period 2 Anticholinergic | 9 | 5 |
| Overall Procholinergic | 38 | 26 |
| Overall Anticholinergic | 41 | 30 |
Collected over All AEs and SAEs are collected on or after the first dosing date through the end of the safety follow up (Day 63 ± 3 days) or EOT+7 (Day 56+7 ±3 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/100 (0%) | 0/100 (0%) | 54/100 (54%) |
| Cohort 2 | 0/73 (0%) | 0/73 (0%) | 44/73 (60.3%) |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| NauseaGastrointestinal disorders | 30/100 | 17/73 |
| DyspepsiaGastrointestinal disorders | 19/100 | 16/73 |
| HeadacheNervous system disorders | 13/100 | 16/73 |
| VomitingGastrointestinal disorders | 17/100 | 13/73 |
| ConstipationGastrointestinal disorders | 13/100 | 12/73 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 7/100 | 8/73 |
| Abdominal discomfortGastrointestinal disorders | 7/100 | 2/73 |
| DizzinessNervous system disorders | 7/100 | 5/73 |
| PruritusSkin and subcutaneous tissue disorders | 2/100 | 5/73 |
| Dry mouthGastrointestinal disorders | 6/100 | 2/73 |
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 100 | 73 | 173 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 27 | 20 | 47 |
| Male | 73 | 53 | 126 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 14 | 32 |
| Not Hispanic or Latino | 82 | 57 | 139 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 75 | 53 | 128 |
| White | 23 | 19 | 42 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Oct 2024 to primary completion in Mar 2025, 4 months.
Results were first posted in Jun 2026, 1 year 3 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 4 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium
Karuna Therapeutics, Inc., a Bristol Myers Squibb company →